Search

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

Cardiologists at the Heart of Cardio-Renal-Metabolic Care | Boehringer Ingelheim US

Cardiologists at the Heart of Cardio-Renal-Metabolic Care

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark

Full data announced in phase III EMPA-KIDNEY trial

The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)

What you need to know about counterfeit medicines

Understand the risk of counterfeit medication.

Growing fresh produce for a cause at our U.S. headquarters

Cooking Up Change: Boehringer Cares Foundation and World Central Kitchen’s Recipe for Fighting Hunger

Our Boehringer Cares team has partnered with World Central Kitchen who aim to address the critical issue of global food insecurity.

Weill Cornell Medicine and NewYork-Presbyterian Hospital join Boehringer Ingelheim to study the incidence of progressive Interstitial Lung Disease in COVID-19 patients

Weill Cornell Medicine And Newyork-presbyterian Hospital Join Boehringer Ingelheim To Study The Incidence Of Progressive Interstitial Lung Disease In Covid-19 Patients

HEARTGARD Plus Save A Heart Initiative | Boehringer Ingelheim US

See how Boehringer Ingelheim, the maker of HEARTGARD Plus, is flying at risk dogs to new homes across the US to celebrate Heartworm Disease Awareness Month

New Platform: Unbridle Your Potential | Boehringer Ingelheim US

Read more on the Boehringer Ingelheim brand platform: Unbridle Your Potential, aimed at providing support and leadership for the equine industry.

Jardiance® (empagliflozin) Tablets Reduce Risk of CV Death | Boehringer Ingelheim US

EMPA-REG OUTCOME® trial: New analyses show that JARDIANCE reduced the risk of CV death in adults with T2D. View ISI, PI and Med Guide.

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes

A day of giving back at Pegasus Therapeutic Riding

Take a look at our volunteer day spent refreshing a farm committed to equine therapy.

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

Boehringer Ingelheim and Vanderbilt University join forces

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies

Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases

Partnering in CardioMetabolic Diseases

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure

New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers